Downloads
Abstract
Overview: According to Globocan 2020, breast cancer is the most frequent neoplasm occurring in women globally and Vietnam. HER2-positive breast cancer is a subtype with a poor prognosis. Therefore, new advancements in treatment, such as Trastuzumab therapy targeting HER-2, have ushered in a new era for treating HER-2 positive breast cancer.
Methods: Retrospective and prospective study at the Oncology Center - Hue Central Hospital from February 2020 to February 2023. The selection criteria included subjects definitively diagnosed with HER-2 positive breast cancer through histopathology and immunohistochemistry in the early breast cancer (EBC).
Results: In our study (n=215), the median age at diagnosis was 50.75 ± 0.72, with stages I-II accounting for 71.2% and regional lymph node metastasis rate being 56.3%. The rates of ER-/PR-; ER+/PR+; ER+/PR-; and ER-/PR+ were 66.5%, 19.5%, 3.7%, and 10.3%, respectively. Low Ki67 (<15%) was present in 21.9% of cases. Trastuzumab therapy was used in 65/215 patients. The study showed that the 2-year disease-free survival (DFS) was 84.7% and the median DFS was 22.2 ± 0.3 months. The most common sites of distant metastases were the lung, the liver and the bone. Poor prognostic factors included T3-T4 disease, positive regional nodes, and lack of access to Trastuzumab.
Conclusion: Patients with HER-2 positive early breast cancer derived substantial benefits from adjuvant Trastuzumab therapy within the first two years following diagnosis. Furthermore, all patients tolerated trastuzumab therapy well.
References
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science. 1987;235(4785):177-182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science. 1989;244(4905):707-712.
Yarden Y. Biology of HER2 and Its Importance in Breast Cancer. Oncology. 2001;61(Suppl. 2):1-13.
Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer. The Oncologist. 2006;11(8):857-867.
Bae SY, Kim S, Lee JH, Lee H-c, Lee SK, Kil WH, et al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15(1):138.
(SRP) SRP, SEER-17, Cancer Stat Facts: Female Breast Cancer Subtypes, 2015-2019.
Phung Thi H, Evaluation of the Outcomes of Adjuvant Chemotherapy Combined with Trastuzumab in Stage II and III Breast Cancer Patients. 2016, Phung Thi Huyen.
Lin NU, Bellon JR, Winer EP. CNS Metastases in Breast Cancer. Journal of Clinical Oncology. 2004;22(17):3608-3617.
Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Research and Treatment. 2013;137(2):449-455.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet. 2007;369(9555):29-36.
Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Research and Treatment. 2013;137(2):523-531.
Piccart M, Procter M, Fumagalli D, Azambuja Ed, Clark E, Ewer MS, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of Clinical Oncology. 2021;39(13):1448-1457.
| Published | 01-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 9 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.9.2 | |
| Keywords | Her-2 dương tính, ung thư vú giai đoạn sớm, liệu pháp Trastuzumab, thời gian sống không bệnh HER-2 positive, early breast cancer, trastuzumab therapy, disease-free survival |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital